(nosocomial infection) [4] . Sixty six cases with 45 deaths (68% of the cases) were reported in two outbreaks [5] . A further small outbreak of five people occurred in Nadia on 2007 with a 100% fatality rate of five people. In Bangladesh, several outbreaks of Nipah encephalitis have been reported. A total of 209 cases in 20 districts of whom 161 (77%) died. The first outbreak was in Meherpur (2001) with death rate of nine out of 13 cases. Since then a series of concurrent epidemics occurred untill 2012. In January 2003, eight deaths (n=12) were reported in Naagaon. and claiming the lives of 14 of the 16 infected people. Whilst 40 out of 44 registered cases died in Lalmohirhat, Dinajpur, Comilla, Nilphamari and Rangpur in early 2011. The final outbreak was in 2012 in Joypurhat, Rajshshi, Natore, and Rajbari with a fatality rate of 83% (n=12). In all instances, the identified risk factors were the consumption of raw date palm sap and direct contact with infected individuals. Infected fruiteating bats (Pteropus bats) were identified as a natural host for NiV [6] . In 2015, the Philippines National Epidemiology Centre received a report of 17 persons (11 with encephalitis, 5 with influenza like illness, and 1 with meningitis) and nonfatal infections with concurrent neurologic diseases and abrupt deaths in several horses. The mode of transmission was from direct exposure to infected horses, contact with contaminated body fluids during slaughtering of sick horses, and / or consumption of undercooked meat from infected horses [7] . Recently, in the third NiV outbreak in India, in Kerala 17 people from the districts of Malapuram and Kozhikode died in June 2018 and two recovered completely. Again, it appeared that fruit eating bats were the primary source of infection and the public is warned not to eat fruits already partly eaten by bats. Since there is currently no effective specific treatment for Nipah virus infection, nor do we have any vaccines against it in humans or in animals, treatment is focused on dealing with the symptoms only. Recently Favipiravir, a purine analogue antiviral drug which was approved in Japan against influenza strains was found to be effective against the Nipah virus in inhibiting the replication and transcription at micromolar concentration in Syrian hamster model. But Favipiravir needs further evaluation before it can be used for the Nipah viruses [8] . Antifusion lipopeptides has been found to be effective in for prophylaxis of lethal NiV in hamster and non-human primates. Antifusion lipopeptide inhibitors with a desired pharmacokinetic property could be targeted against NiV in future [9] . For Public Health surveillance and multidisciplinary approaches on investigations and therapy and development of vaccines are vital. As with all emerging viruses harmful to humans, an effective system for the detection of infectious diseases as well as for the identification for new causes, risk factors and characteristics in challenged settings is crucial to reduce the disease burden in the population.
